Abbott Laboratories (ABT.N)
ABT.N on New York Stock Exchange
75.25USD
15 Feb 2019
75.25USD
15 Feb 2019
Change (% chg)
$1.28 (+1.73%)
$1.28 (+1.73%)
Prev Close
$73.97
$73.97
Open
$74.48
$74.48
Day's High
$75.39
$75.39
Day's Low
$74.33
$74.33
Volume
3,090,043
3,090,043
Avg. Vol
2,003,758
2,003,758
52-wk High
$75.39
$75.39
52-wk Low
$56.81
$56.81
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.61 | December | 18 Feb 2019 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 9 | 9 | 9 | 8 |
| (2) OUTPERFORM | 9 | 9 | 8 | 7 |
| (3) HOLD | 2 | 2 | 3 | 4 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 1 | 1 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.81 | 1.81 | 1.70 | 1.79 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 18 | 7,471.90 | 7,530.52 | 7,441.00 | 7,673.38 |
| Quarter Ending Jun-19 | 18 | 7,947.60 | 8,032.00 | 7,801.00 | 8,156.92 |
| Year Ending Dec-19 | 20 | 31,842.60 | 31,985.60 | 31,691.40 | 32,771.40 |
| Year Ending Dec-20 | 20 | 34,046.00 | 34,855.00 | 33,651.10 | 34,726.90 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | 20 | 0.61 | 0.63 | 0.60 | 0.64 |
| Quarter Ending Jun-19 | 20 | 0.80 | 0.82 | 0.77 | 0.79 |
| Year Ending Dec-19 | 22 | 3.21 | 3.26 | 3.18 | 3.21 |
| Year Ending Dec-20 | 22 | 3.60 | 3.70 | 3.48 | 3.58 |
| LT Growth Rate (%) | 6 | 10.74 | 12.50 | 7.10 | 11.72 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-18 | 7,816.24 | 7,765.00 | 51.24 | 0.66 |
| Quarter Ending Sep-18 | 7,650.64 | 7,656.00 | 5.36 | 0.07 |
| Quarter Ending Jun-18 | 7,711.53 | 7,767.00 | 55.47 | 0.72 |
| Quarter Ending Mar-18 | 7,285.94 | 7,390.00 | 104.06 | 1.43 |
| Quarter Ending Dec-17 | 7,385.90 | 7,589.00 | 203.10 | 2.75 |
| Earnings (per share) | ||||
| Quarter Ending Dec-18 | 0.81 | 0.81 | 0.00 | 0.01 |
| Quarter Ending Sep-18 | 0.75 | 0.75 | 0.00 | 0.58 |
| Quarter Ending Jun-18 | 0.71 | 0.73 | 0.02 | 2.86 |
| Quarter Ending Mar-18 | 0.58 | 0.59 | 0.01 | 1.71 |
| Quarter Ending Dec-17 | 0.73 | 0.74 | 0.01 | 1.07 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 7,471.90 | 7,471.90 | 7,620.39 | 7,655.17 | 7,673.38 |
| Quarter Ending Jun-19 | 7,947.60 | 7,947.60 | 8,059.65 | 8,077.47 | 8,156.92 |
| Year Ending Dec-19 | 31,842.60 | 31,842.60 | 32,188.90 | 32,214.20 | 32,771.40 |
| Year Ending Dec-20 | 34,046.00 | 34,046.00 | 34,359.80 | 34,340.60 | 34,726.90 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | 0.61 | 0.61 | 0.65 | 0.66 | 0.64 |
| Quarter Ending Jun-19 | 0.80 | 0.80 | 0.80 | 0.80 | 0.79 |
| Year Ending Dec-19 | 3.21 | 3.21 | 3.20 | 3.20 | 3.21 |
| Year Ending Dec-20 | 3.60 | 3.60 | 3.61 | 3.60 | 3.58 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Mar-19 | 0 | 0 | 0 | 12 |
| Quarter Ending Jun-19 | 0 | 0 | 2 | 10 |
| Year Ending Dec-19 | 0 | 0 | 4 | 15 |
| Year Ending Dec-20 | 0 | 0 | 5 | 12 |
| Earnings | ||||
| Quarter Ending Mar-19 | 0 | 0 | 0 | 14 |
| Quarter Ending Jun-19 | 0 | 0 | 11 | 4 |
| Year Ending Dec-19 | 0 | 0 | 12 | 3 |
| Year Ending Dec-20 | 0 | 0 | 8 | 9 |
Earnings vs. 
Estimates- Smith & Nephew in talks to buy NuVasive for over $3 billion - FT
- Smith & Nephew in talks to buy NuVasive for over $3 billion: FT
- UPDATE 2-Smith & Nephew in talks to buy NuVasive for over $3 bln - FT
- UPDATE 3-AbbVie expects steeper decline in Humira's overseas sales; shares fall
- AbbVie profit misses as Humira faces biosimilar challenge in Europe